GHK-Cu Adult (30-49) Monitoring: What to Track and When

Why is there no standard schedule?

FDA has approved no drug containing GHK-Cu; it treats GHK-Cu as a nominated bulk drug substance for compounding, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [1][7]. For injectable GHK-Cu, FDA lists the substance in the nominated-but-withdrawn table and states that compounded injectable drugs containing GHK-Cu may pose a risk for immunogenicity due to aggregation and peptide-related impurities, with limited human data to inform safety [2]. Non-injectable GHK-Cu is in category 1, the group under evaluation for the bulks list [1].

Topical copper peptide creams are a different regulatory product: cosmetics do not need FDA approval before sale, and a product becomes a drug when it claims to treat disease or change the body's structure or function [3]. An injectable GHK-Cu product is neither a cosmetic nor FDA-approved [3].

What did the human trials measure?

Miller and colleagues randomized patients after CO2 laser resurfacing around the mouth to skin care with or without GHK-Cu; 13 patients completed. Redness assessments found no significant difference between groups during follow-up, and at 12 weeks objective assessments found no difference in wrinkles or overall skin appearance. A patient questionnaire showed a significant difference in overall skin quality favoring GHK-Cu (P=.04) [5]. That 12-week point followed a laser procedure; it does not set a monitoring interval for other uses.

In a trial of 86 evaluable patients with venous stasis ulcers, a 0.4% tripeptide copper complex cream was no different from an inert vehicle on ulcer size, while silver sulfadiazine 1% reduced it [4]. A 2026 systematic review kept 64 records and reported that most randomized trials are small and use facial cosmetic creams, and that microneedle delivery has not been tested in a single registered, adequately powered human randomized trial [8].

What is worth recording?

The exact product, route and strength (for a topical, the name and strength of the copper peptide cream you use); other copper-containing supplements; any liver disease or known copper-metabolism disorder; the outcome you want to change, measured at baseline and compared at a time relevant to your goal; and any new symptoms with dates.

Which label facts bear on copper tests?

One FDA-approved copper label that bears on copper tests is Copper (Cupric Chloride Injection), an intravenous additive for total parenteral nutrition. It is a different product from GHK-Cu, and its instructions apply to people receiving that injection. It states that copper is mainly eliminated in bile, that excretion falls in cholestasis and cirrhosis, and that hepatic accumulation has been reported at doses above those recommended; for patients receiving it who have cholestasis, biliary dysfunction or cirrhosis, it advises monitoring hepatic and biliary function and obtaining serum copper and ceruloplasmin if hepatobiliary signs appear [6]. Normal serum copper values on that label range from 80 to 163 mcg/dl, mean about 110 mcg/dl [6]. No GHK-Cu-specific blood-test schedule is established.

Oral contraceptive use is a confounder: in a cross-sectional survey of 610 healthy women aged 18 to 44, use was associated with higher serum copper, from 34% (95% CI 24 to 45) with levonorgestrel to 55% (37 to 76) with antiandrogen progestins [9]. We found no human study measuring blood copper levels during GHK-Cu use. A laboratory study found that copper passed through isolated human skin when a copper tripeptide was applied in vitro [10]; it does not show how blood copper changes in people using GHK-Cu.